Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Pancreatic Neoplasms 5Colorectal Neoplasms 5Osteosarcoma 2Neoplasms 2Wilms Tumor 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Metastatic Gastric Adenocarcinoma 1Malignant Ascites 1Locally Advanced Unresectable Gastric Adenocarcinoma 1Hepatoblastoma 1Glioblastoma 1Gastrointestinal Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Biliary Tract Neoplasms 1Advanced Pancreatic Cancer (Part 1) 1

Interventions

Temozolomide 3Peripheral Blood Stem Cell Transplantation 3talazoparib 2Filgrastim 2lenvatinib 1irinotecan sucrosofate 1holmium-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetrakis(methylenephosphonic acid) 1etoposide phosphate 1efineptakin alfa 1Radiotherapy 1Radiosurgery 1Nivolumab 1Microarray Analysis 1Melphalan 1Ipilimumab 1Immunohistochemistry 1Ifosfamide 1HhAntag691 1Everolimus 1Dasatinib 1Cyclophosphamide 1Carboplatin 1CTLA-4 Antigen 1Blotting, Western 1Amifostine 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neuroectodermal Tumors, Primitive, Peripheral × irinotecan sucrosofate × Clear all
NCT04901702 2026-05-19

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
90 enrolled
CNSGastrointestinalGenitourinarySarcoma

Neoplasms, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡